Newest figures come from the 10-Q for Q2 FY2026, filed Aug 10, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the APGE SEC filings page.
This page shows Apogee Therapeutics, Inc. (APGE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Apogee operates as a research-led development business whose expansion is funded mainly through equity rather than operating receipts.
R&D spending rose from$68.4M in FY2023 to$214.7M in FY2025, while operating cash outflow expanded from$74.8M to$227.5M . That parallel movement shows the enlarged research program is driving funding needs; the reported operating model is not yet self-financing.
Balance-sheet expansion continued in FY2025 even as liabilities fell
Free cash flow was
Financial Health Signals
We do not publish a peer-relative financial health score for Apogee Therapeutics, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Apogee Therapeutics, Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Apogee Therapeutics, Inc. reported a net loss of $255.8M while operations used $227.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Apogee Therapeutics, Inc.'s EBITDA was -$95.6M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Apogee Therapeutics, Inc. reported a net loss of $85.9M in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Apogee Therapeutics, Inc. earned -$1.14 per diluted share (EPS) in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q2 2026.
Cash & Balance Sheet
Apogee Therapeutics, Inc. held $105.6M in cash as of Q2 2026; no long-term debt figure is on record for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Apogee Therapeutics, Inc.'s quarterly ROE was -7.2% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is up 3.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.3 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Apogee Therapeutics, Inc. invested $67.3M in research and development in Q2 2026. This represents an increase of 20.8% from the same quarter a year earlier. Against the prior quarter it is up 10.7%.
Not reported for Q2 2026.
Not reported for Q2 2026.
APGE Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $67.3M+20.8% | $60.8M+31.1% | $58.4M-3.0% | $54.2M+18.5% | $55.7M+67.7% | $46.4M+61.5% | $60.2M+108.0% | $45.7M+167.8% |
| SG&A Expenses | $24.3M+39.4% | $22.0M+31.4% | $19.6M+25.3% | $17.1M+31.8% | $17.5M+60.0% | $16.7M+76.5% | $15.7M+90.9% | $13.0M+79.3% |
| Operating Income | -$96.0Mn/m | -$82.8Mn/m | -$78.1Mn/m | -$71.3Mn/m | -$73.2Mn/m | -$63.1Mn/m | -$75.9Mn/m | -$58.7Mn/m |
| EBITDA | -$95.6Mn/m | -$82.4Mn/m | -$77.7Mn/m | -$70.9Mn/m | -$72.8Mn/m | -$62.9Mn/m | -$75.8M | -$58.6M |
| Interest Expense | $1.6M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $78K+8.3% | $79K-4.8% | $62K+244.4% | $61Kn/m | $72Kn/m | $83Kn/m | $18K | $0 |
| Net Income | -$85.9Mn/m | -$74.1Mn/m | -$69.4Mn/m | -$65.0Mn/m | -$66.1Mn/m | -$55.3Mn/m | -$67.2Mn/m | -$49.0Mn/m |
| EPS (Basic) | -$1.14n/m | -$1.06n/m | -$1.03n/m | -$1.11n/m | -$1.13n/m | -$0.95n/m | -$1.19 | -$0.86n/m |
| EPS (Diluted) | -$1.14n/m | -$1.06n/m | -$1.03n/m | -$1.11n/m | -$1.13n/m | -$0.95n/m | -$1.19 | -$0.86n/m |
| Diluted Shares (Avg) | 75M+29.1% | 70M+19.7% | N/A | 59M+3.5% | 58M+3.4% | 58M+16.0% | N/A | 57M+37.7% |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
APGE Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'25Filing | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.3B+103.1% | $1.3B+81.1% | $937.1M+24.3% | $626.2M-19.3% | $657.8M-17.8% | $714.2M-13.3% | $754.0M+87.8% | $776.3M+82.0% |
| Current Assets | $991.7M+92.2% | $1.1B+105.9% | $741.4M+40.0% | $540.1M+1.1% | $516.1M-24.3% | $521.5M-36.4% | $529.7M+33.0% | $534.5M+25.3% |
| Cash & Equivalents | $105.6M-15.0% | $451.8M+322.6% | $131.5M-7.2% | $107.9M-9.1% | $124.2M-59.6% | $106.9M-78.0% | $141.8M+19.8% | $118.8M-36.9% |
| Short-Term Investments | $866.4M+127.3% | $608.1M+49.6% | $598.6M+58.0% | $419.4M+3.0% | $381.2M+3.3% | $406.4M+22.9% | $378.9M+36.7% | $407.3M+73.6% |
| Long-Term Investments | $321.9M+178.1% | $198.4M+18.0% | $172.7M-17.9% | $61.6M-72.9% | $115.8M+2.1% | $168.1Mn/m | $210.4Mn/m | $227.7Mn/m |
| Total Liabilities | $141.2M+268.0% | $37.9M-7.2% | $33.3M-10.5% | $39.8M-4.9% | $38.4M+42.0% | $40.8M+83.9% | $37.2M+72.9% | $41.9M+143.8% |
| Current Liabilities | $37.5M+18.9% | $33.0M0.0% | $27.9M-2.3% | $34.0M+4.4% | $31.6M+28.2% | $33.0M+52.9% | $28.6M+38.9% | $32.6M+89.8% |
| Non-Current Liabilities | $103.7M+1420.5% | $4.9M-37.4% | $5.3M-37.8% | $5.8M-37.7% | $6.8M+184.0% | $7.8M+1144.4% | $8.6M+821.4% | $9.3Mn/m |
| Total Equity | $1.2B+92.9% | $1.3B+86.5% | $903.9M+26.1% | $586.3M-20.2% | $619.4M-19.9% | $673.4M-16.0% | $716.8M+88.7% | $734.4M+79.5% |
| Retained Earnings | -$721.7Mn/m | -$635.9Mn/m | -$561.8Mn/m | -$492.4Mn/m | -$427.4Mn/m | -$361.3Mn/m | -$305.9Mn/m | -$238.7Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
APGE Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$71.4Mn/m | -$55.6Mn/m | -$62.7Mn/m | -$54.3Mn/m | -$62.0Mn/m | -$48.5Mn/m | -$67.7Mn/m | -$42.5Mn/m |
| Depreciation & Amortization | $400K0.0% | $408K+97.1% | $406K+434.2% | $400K+733.3% | $400K+1011.1% | $207K+613.8% | $76K | $48K |
| Stock-Based Compensation | $16.7M+46.9% | $17.2M+54.2% | N/A | $11.9M+103.4% | $11.3M+99.1% | $11.1M+165.8% | N/A | $5.8M+288.0% |
| Capital Expenditures | N/A | N/A | $62K | $0-100.0% | $768K+1405.9% | $4.3M+1129.9% | N/A | $751K |
| Free Cash Flow | N/A | N/A | -$62.8M | -$54.3Mn/m | -$62.8Mn/m | -$52.8Mn/m | N/A | -$43.3M |
| Investing Cash Flow | -$381.9M-588.8% | -$35.3M-372.3% | -$288.6M-722.5% | $17.9Mn/m | $78.1Mn/m | $13.0Mn/m | $46.4Mn/m | -$146.4M |
| Financing Cash Flow | $107.0M+8969.2% | $411.2M+66004.0% | $374.9M+745.3% | $19.7M+5053.5% | $1.2Mn/m | $622K-99.9% | $44.4Mn/m | $383K-99.9% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
APGE Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -7.2%+3.5pp | -5.9%+2.3pp | -7.7%+1.7pp | -11.1%-4.4pp | -10.7%-6.3pp | -8.2%-4.2pp | -9.4%-1.0pp | -6.7%-1.6pp |
| Return on Assets | -6.4%+3.6pp | -5.7%+2.0pp | -7.4%+1.5pp | -10.4%-4.1pp | -10.1%-5.8pp | -7.8%-3.9pp | -8.9%-1.0pp | -6.3%-1.4pp |
| Current Ratio | 26.44+10.1x | 32.59+16.8x | 26.57+8.0x | 15.86-0.5x | 16.36-11.3x | 15.82-22.3x | 18.55-0.8x | 16.39-8.4x |
| Liabilities-to-Equity | 0.12+0.1x | 0.030.0x | 0.040.0x | 0.070.0x | 0.060.0x | 0.060.0x | 0.050.0x | 0.060.0x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Apogee Therapeutics, Inc. APGE | FY2025 | N/A | -$255.8M | N/A | N/A | — |
| Spyre Therapeutics, Inc. SYRE | FY2025 | $0 | -$155.2M | N/A | $8.9B | — |
| Nektar Therapeutics NKTR | FY2025 | $55.2M | -$164.1M | N/A | $1.0B | 50/100 |
| Oruka Therapeutics, Inc. ORKA | FY2025 | N/A | -$105.4M | N/A | $6.5B | — |
| Celldex Therapeutics, Inc CLDX | FY2025 | $1.5M | -$258.8M | N/A | $2.2B | 56/100 |
| Jade Biosciences, Inc. JBIO | FY2025 | N/A | -$127.4M | N/A | $1.1B | — |
Where Apogee Therapeutics, Inc. Ranks
Frequently Asked Questions
No, Apogee Therapeutics, Inc. (APGE) reported a net loss of $255.8M in fiscal year 2025.
Apogee Therapeutics, Inc. (APGE) had EBITDA of -$284.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Apogee Therapeutics, Inc. (APGE) has a return on equity of -28.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Apogee Therapeutics, Inc. (APGE) recorded an outflow of $232.6M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Apogee Therapeutics, Inc. (APGE) recorded an outflow of $227.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Apogee Therapeutics, Inc. (APGE) had $937.1M in total assets as of fiscal year 2025, including both current and long-term assets.
Apogee Therapeutics, Inc. (APGE) invested $5.1M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Apogee Therapeutics, Inc. (APGE) invested $214.7M in research and development during fiscal year 2025.
Apogee Therapeutics, Inc. (APGE) had a current ratio of 26.57 as of fiscal year 2025, which is generally considered healthy.
Apogee Therapeutics, Inc. (APGE) had a liabilities-to-equity ratio of 0.04 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
Apogee Therapeutics, Inc. (APGE) had a return on assets of -27.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
At the end of fiscal year 2025, Apogee Therapeutics, Inc. (APGE) held $902.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $227.4M over that year. Dividing the one by the other, the reported balance equals about 48 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Apogee Therapeutics, Inc. (APGE) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Apogee Therapeutics, Inc. (APGE) reported a net loss of $255.8M while operations used $227.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.